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Bone metastases are a common clinical problem, affecting 70%
of women with breast cancer (Coleman and Rubens, 1987).
Difficulties with objective assessment of response to treatment
by conventional radiological means, particularly in women with
sclerotic or mixed lytic-sclerotic metastases, have led to the inves-
tigation of biochemical markers of bone metabolism as potentially
useful indicators of disease response (Coleman et al, 1992).
Urinary hydroxyproline excretion is the most studied marker of
bone resorption but is not specific for bone collagen breakdown
and is affected by changes in diet as well as soft tissue destruction
by disease (Robins et al, 1982; Moro et al, 1993). Urinary calcium
excretion is normal in patients with predominantly sclerotic
disease and in patients whose tumours produce parathyroid
hormone-related protein (PTHrP), which increases renal tubular
reabsorption of calcium (Coleman et al, 1992; Sano et al, 1994).
Pyridinoline (Pyr) and deoxypyridinoline (Dpyr) are cross-links
between collagen molecules, and are broken down and released
during bone resorption (Fujimoto, 1980; Eyre, 1992). Excretion of
the cross-links is unaffected by diet. Dpyr is only found in bone
and dentine collagen and thus its excretion is potentially specific
for bone collagen breakdown (Robins, 1982). Preliminary results
suggest that Dpyr excretion has significant advantages over
hydroxyproline as a urinary marker of bone resorption in osteo-
porotic patients (Eastell et al, 1990; Delmaset al, 1991; Paterson
et al, 1991).
Urinary excretion of cross-links has been reported to be
elevated in patients with breast and prostate cancer (Sano et al,
1994) and to fall when bone metastases are treated by anti-
resorptive drugs such as bisphosphonates (Coleman et al, 1992).
The aim of this study was to assess the ability of two urinary
cross-link markers to predict response to hormonal treatment in
patients with breast cancer bone metastases. These analytes were
measured serially and compared with serum levels of the breast
tumour-associated antigen CA15-3 (Robertson et al, 1991) and
standard International Union Against Cancer (UICC) radiological
criteria of response (Hayward et al, 1977).
PATIENTS AND METHODS
Patients
Thirty-six women with breast cancer presenting with metastatic
disease in the skeleton were prospectively studied. At relapse or
progression of their disease, women were either being treated
with adjuvant tamoxifen 20 mg day–1 (n = 13), megesterol acetate
(n = 3), radiotherapy induced ovarian ablation (n = 1), or on no
treatment (n = 19). Four patients presented synchronously with
bone metastases and a palpable breast lump.
The diagnosis of bone metastases in all women was made by
a radioisotope bone scan at presentation combined with plain
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Correspondence to: NJ Bundredradiographs of the chest, pelvis and lumbar spine. Radiographs
were also taken of any areas of activity on the radioisotope scan or
any clinically symptomatic areas of the skeleton. Twelve patients
had disease in other sites (soft tissue, n = 8; lung, n = 7; liver,
n = 2; brain, n = 1) (Table 1). Sequential radiological monitoring
was performed with plain radiographs of the chest, pelvis, lumbar
spine and any other affected bones every 3 months. Response to
treatment for patients with lytic metastases was assessed by stan-
dard radiological UICC criteria at 3 and 6 months, or at disease
progression (Hayward et al, 1977). The radiological response to
treatment was assessed independently by a consultant radiologist
and confirmed by a medical oncologist without knowledge of the
cross-link results. Patients with an increase in the number of
metastases, or size of metastases, or the development of further
lytic metastases were regarded as having progressive disease.
Patients with solely sclerotic metastases were not evaluable
according to UICC criteria and were excluded from the study.
However, patients with mixed sclerotic and lytic disease, or
patients with sclerotic metastases who had clearly evaluable areas
of soft tissue disease were included.
For analysis, patients with responding or stable disease for more
than 6 months were grouped together as these categories have
been shown to demonstrate equivalent response (Robertson et al,
1997). At relapse with bone metastases, all patients were fully
staged radiologically and by liver function tests. Subsequently
they were started on tamoxifen 20 mg day–1 (n = 21), megesterol
acetate 160 mg day–1 (n = 5), Zoladex (n = 2), aminoglutethamide
(n = 3), arimidex (n = 1) and chemotherapy (n = 1). Three women
had been on adjuvant tamoxifen for over 5 years, and it was felt
they might respond to tamoxifen withdrawal, thus they were given
no treatment. No patient had received bisphosphonate therapy or
skeletal radiotherapy prior to, or during, the study period. The
study was approved by the Hospital Ethics Committee and all
patients gave informed consent.
Methods
Blood samples were collected at each clinic visit, centrifuged, and
stored at –20°C. Urine for measurement of Pyr, Dpyr, calcium,
creatinine and cyclic adenosine monophosphate (cAMP) was
collected between 10:00 h and 12:00 h, from patients who had
fasted overnight. Urine was stored at –20°C after the addition of
3% hydrochloric acid. All samples were coded, and all samples
from individual patients were assayed in the same batch.
Following acid hydrolysis of urine at 110°C overnight, and partial
purification on a CF1 cellulose column, Pyr and Dpyr were
separated by reverse phase high-performance liquid chroma-
tography (HPLC) and detected by fluorescence (Colwell et al,
1993). The intra-assay coefficients of variation for Pyr and Dpyr
were 7% and 10% respectively, and for inter-assay variation were
<10%. Age-matched post-menopausal women had absolute ranges
of Pyr of 12–40 nmol mmol–1 creatinine, and Pyr 3–11 nmol
mmol–1 creatinine (Colwell et al, 1993). The upper limits of
normal for this study were therefore the highest levels measured
in age-matched controls; Pyr 40 nmol mmol–1 creatinine and Dpyr
11 nmol mmol–1 creatinine.
Urine excretion of cAMP was measured by radioimmunoassay
(Amersham UK), and was expressed as nmol l–1 glomerular
filtrate. The fasting molar ratio of urinary calcium to creatinine
(CaCr–1 mmol mmol–1) was multiplied by the serum creatinine to
calculate calcium excretion (CaE). CaE was then compared with
serum calcium to assess the renal tubular reabsorption of calcium
(Peacock et al, 1969).
Serum calcium, creatinine, albumin, and alkaline phosphatase
were measured by standard automated methods. Serum calcium
was adjusted to an albumin concentration of 40 g l–1 (adjusted
serum calcium = measured calcium mmol l–1 +0.02[40-measured
albumin]). Blood for assay of plasma PTHrP was collected in
EDTA after the addition of 200 IU of Trasylol, and separated by
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Table 1
Responders Progressors
Age 56 years 58 years
(range) (42–69) (36–82)
Disease-free interval from  51 months 12 months
primary treatment (0–276) (0–168)
Number of initia bone  3 5
metastases (1–12) (1–12)
Type of metastases
Lytic 6 12
Mixed 11 7
Other metastases
Soft tissue 5 3
Lung 2 5
Liver 1 1
Brain 0 1
Previous treatmenta
None 10 9
Tamoxifen 7 6
Megace 0 3
DXT ovarian ablation 0 1
Treatment
None (withdrawal) 2 1
Tamoxifen 10 11
Megace 3 2
Aminoglutethamide 1 2
Zoladex 1 1
Arimidex 0 1
Chemotherapy 0 1
a This includes 13 patients already on endocrine treatment for bone
metastases, and 3 for soft tissue disease.
Table 2
Responders Progressors Range
n 17 19
Serum calcium 2.29 2.32 2.1–2.6
mmol l–1 (2.05–2.54) (2.08–2.56) NS
Urine calcium– 0.38 0.46 <0.5
creatinine ratio (0.01–0.99) (0.05–1.24) NS
Calcium excretion 38 49
mmol LGF–1 (1–102) (7–118) NS
Urine cAMP 36 61 <60
nmol LGF–1 (6–86) (24–126) P < 0.05)
Pyr 56 164 <40
nmol mmol–1 (20–75) (35–291) P < 0.01
creatinine
Dpyr 14 40 <11
nmol mmol–1 (6–22) (9–80) P < 0.02
creatinine
PTHrP <0.23 <0.23 <0.23
pmol l–1 (<0.23–0.76) (<0.23–0.65) NS
CA 15-3 99 210 <30
IU (11–498) (29–853) P < 0.05centrifugation within 15 min. Plasma PTHrP (1–86) was measured
by a sensitive two-site immunoradiometric assay (normocalcaemic
controls <0.23 pmol l–1) (Ratcliffe et al, 1993). Serum CA15-3 was
measured by an immunoradiometric assay (CIS UK Ltd; healthy
controls >30 U ml–1).
The percentage change of biochemical markers was calculated
by using each patient as her own control. The subsequent increase
or decrease in each tumour marker are expressed as a percentage
change from the original value. This enables a comparison of
magnitude of change between each tumour marker without any
confusion as to the importance of absolute values. Variations of
tumour markers within the reference range for healthy controls
were recorded as no percentage change.
Statistical analysis was performed by Spearman rank correla-
tion, Kruskal–Wallis three-way analysis, Mann–Whitney U-tests,
and multiple analysis of variance where appropriate.
RESULTS
UICC assessment of disease response
The frequency of metastases in sites other than bone was equally
distributed between patients with responding and progressing
disease (Table 1). As evaluated by UICC criteria at 6 months, or at
disease progression, 19 patients had radiological evidence of
progressive disease, and 17 patients either had stable disease or a
partial response. The median duration of response was 10 months
(range 6–24 months). The median number of bone metastases
initially detected in the women with progressive bone disease was
five (range 1–12), and was not significantly different from the
number found in women whose disease responded (median three,
range 1–12). Eighteen women had lytic bone metastases, 14 had
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Table 3
Marker Upper 95% CI Sensitivity Specificity Positive
for responders prediction prediction
CA 15-3 IU l–1 >60 80% 77% 78%
Pyr nmol mmol–1 >70 80% 93% 93%
creatinine
Dpyr >22 84% 95% 95%
nmol mmol–1 creatinine
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Figure 1 (A) Initial urinary excretion of pyridinoline (Pyr) in progressors and
responders, in patients with purely lytic, or mixed lytic/sclerotic bone
metastases (data shown as absolute range and mean values). (B) Initial
urinary excretion of deoxypyridinoline (Dpyr) in progressors and responders,
in patients with purely lytic, or mixed lytic/sclerotic bone metastases (data
shown as absolute range and mean values). (C) Initial serum CA15-3 in
progressors and responders, in patients with purely lytic, or mixed
lytic/sclerotic bone metastases (data shown as absolute range and mean
values)mixed sclerotic/lytic metastases, and four had sclerotic metastases
with easily evaluable soft tissue metastases.
Measurement of urinary cross-link excretion at the start of the
study showed that Pyr correlated with Dpyr (r = 0.85, P < 0.0001).
The number of bone metastases was not related to the urinary
levels of the two bone resorption markers and there was no signif-
icant relationship between them and the number of bone metas-
tases at presentation. The frequency of metastases in sites other
than bone was equally distributed between the progressive and
non-progressive groups (Table 1).
Biochemical parameters at the start of the study
A series of urine and biochemical measurements were made at the
beginning of the study in order to see if any measurement
predicted disease response (Table 2). Excretion of Pyr was signifi-
cantly higher in patients whose disease subsequently progressed
(mean 164 nmol mmol–1 creatinine, range 35–291) compared with
a mean of 56 nmol mmol–1 creatinine (range 20–75) in women
who responded (partial response and stable disease) (P < 0.01)
(Figure 1A).
Excretion of Dpyr was also higher in women with disease that
progressed, mean 40 nmol mmol–1 creatinine (range 9–80)
compared with a mean value in responders of 14 nmol mmol–1
creatinine (range 6–22) (P < 0.02) (Figure 1B). Tumour marker
serum CA15-3 was also significantly higher in progressors (mean
210 IU, range 29–853) compared with responders (mean 99 IU,
range 11–498) (Figure 1C) (P < 0.05). Serum CEA was also higher
in progressors (mean 57, range 4–470) than in responders (mean
23, range 4–150) (P < 0.05).
Serum calcium, urine calcium/creatinine ratio, calcium excre-
tion and plasma PTHrP were non-predictive (Table 2). Although
urine cAMP was significantly higher at the beginning of the study
in progressors, sequential changes were not predictive (Table 2).
The specificity and sensitivity of three predictive assays (Pyr,
Dpyr and CA15-3) are shown in Table 3.
Patients with responding bone metastases
Pyr and Dpyr excretion was within the normal range in 50% and
60% of cases respectively. Furthermore, the urinary concentrations
of Pyr and Dpyr did not change significantly throughout the period
of urine cross-link sampling, which was for a median of 6 months
(range 3–12), and demonstrated for the first 2 months by Figure
2A and B.
Patients with progressive bone metastases
At initial diagnosis of skeletal metastases, urinary Pyr and Dpyr
were increased in 100% and 85% of patients, respectively, who
subsequently developed progressive disease (Figure 1A,B). The
median follow-up time for a patient with progressive disease was
4 months (range 2–11). Over the period of monitoring, urinary Pyr
and Dpyr excretion increased in all patients with progressive
disease, compared with the levels at presentation. The initial rise
in excretion preceded radiological evidence of disease progression
by a median of 2 months (Figure 2A,B). The increases in Pyr and
Dpyr excretion were significant at 8 weeks (P < 0.04), and also at
12 weeks (P < 0.005) (Figure 2A,B).
Calcium excretion and PTHrP levels
Urinary calcium excretion at presentation did not differ signifi-
cantly between the patients who progressed or responded; mean
49 mmol LGF–1 (range 7–118) and 38 mmol LGF–1 (range 1–102)
respectively. Neither calcium excretion nor the urinary
calcium–creatinine ratio correlated with disease response. Renal
tubular reabsorption of calcium was within the normal range for
all patients. Plasma PTHrP levels were similar in both groups of
patients: the median in the progressive group was <0.23 pmol l–1
(range <0.23–0.65) and for the non-progressive group was
<0.23 pmol l–1 (range <0.23–0.76).
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Figure 2 (A) Changes in Pyridinoline (Pyr) excretion in progressors and responders, over the first two months of the study period (data shown as median
values and standard deviation) (B) Changes in Deoxypyridinoline (Dpyr) excretion in progressors and responders, over the first two months of the study period
(data shown as median values and standard deviation). Note: patients with progressive disease had further increase in pyridinoline and deoxypyridinolineComparison with changes in serum CA15-3 levels
In all patients, initial urinary Pyr and Dpyr levels correlated with
serum CA15-3 (r = 0.86, P = 0.006; and r = 0.8, P = 0.01 respec-
tively). In the group who progressed, median CA15-3 levels rose,
and in the responders, median CA15-3 levels remained stable
confirming the radiological UICC assessment of disease progres-
sion. However, CA15-3 levels increase from the first measurement
in some responders, and decreased in some progressors (Figure
3A,B).
DISCUSSION
The recent development of sensitive biochemical markers to deter-
mine changes in bone metabolism has provided new insights into
the mechanisms of progression of bone metastases in women with
breast cancer. Pyr and Dpyr have both been shown to be more
sensitive than urinary hydroxyproline in monitoring bone resorp-
tion (Eastell et al, 1990; Bettica et al, 1992; Colwell et al, 1993).
We have confirmed the preliminary findings of a recent study
which reported increased Pyr and Dpyr in patients with bone
metastases from breast cancer (Paterson et al, 1991). Dpyr has
previously been shown to decrease transiently in 20 patients with
bone metastases undergoing chemotherapy, suggesting that Dpyr
may be a useful early marker of disease response to therapy (Wada
et al, 1993). We have demonstrated that the initial urine levels of
Pyr and Dpyr in patients presenting with bone metastases allows
prediction of future outcome of the disease. The positive predic-
tive values that indicated the disease progression for Pyr and Dpyr
were 95% and 100% for urine levels of 70 and 22 nmol mmol–1
creatinine respectively. This compares very favourably with the
standard tumour marker Ca15-3, where even with levels twice the
upper limit of normal, sensitivity and specificity for disease
progression was only 82% and 79%. Both Pyr and Dpyr increased
significantly within 8 weeks in progressors. The measurement of
urinary cross-links provided objective disease response assess-
ment by 2 months compared to the standard criteria, which require
3–6 months of radiological assessment (Hayward et al, 1977;
Coleman et al, 1998). Biochemical markers would thus allow
earlier changes of therapy for women with progressive disease and
may result in better patient outcomes.
CA 15-3 is released from human tumour cells, and is the most
reliable biochemical tumour marker currently available for moni-
toring response to treatment in patients with advanced breast
cancer. Although increased levels of CA 15-3 are useful, rises in
CA 15-3 can occur in the first 3 months in some patients who
subsequently respond to therapy, and should be regarded with
caution. In contrast, Pyr and Dpyr are released from the bone
matrix by osteoclast-mediated resorption stimulated by the
tumour-produced factors. CA 15-3 is not produced by every
tumour and does not always reliably increase even when the
tumour is progressing (Robertson et al, 1991). However, CA 15-3
is of great value for monitoring metastases at other sites. Women
who present with elevated urinary levels of cross-links appear to
respond poorly to changes in hormonal therapy.
Breast cancer may affect bone metabolism, producing increased
bone resorption with or without an associated increase in bone
formation (Delmas et al, 1991; Sano et al, 1994). Bone resorption
is increased by factors released by breast cancer cells such as
PTHrP, TGF-a, or prostaglandins, which may stimulate osteo-
clastic activity either locally or via the bloodstream (Mundy et al,
1985). Bone metastases usually stimulate bone resorption more
than bone formation and thus markers of bone formation, e.g. alka-
line phosphatase, are not as valuable markers of disease activity as
markers of bone degradation such as Pyr and Dpyr.
Urinary cAMP excretion was raised at presentation in those
patients who subsequently had progressive disease. It did not,
however, rise sequentially with disease progression, and could not
be utilized as a marker of disease response. Urinary cAMP was
elevated in the absence of raised PTHrP, and this may reflect the
Urinary collagen breakdown products in breast cancer 1269
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Figure 3 (A) Percentage change in urinary excretion of Pyr and Dpyr, and serum CA15-3 over the first 2-month period of observation in patients who
subsequently remained stable or responded to treatment. Patients who remained within the reference ranges/normal limits are represented as no percentage
change. Results are expressed as absolute range and mean change. (B) Percentage change in urinary excretion of Pyr and Dpyr, and serum CA15-3 over the
first 2-month period of observation in patients who subsequently progressed on treatment. Patients who remained within the reference ranges/normal limits are
represented as no percentage change. Results are expressed as absolute range and mean changeactions of an as yet unidentified tumour product that affects the
kidney.
In contrast to previous authors (Coleman et al, 1988; Dodwell
et al, 1990) we were unable to demonstrate a significant increase
in urinary calcium excretion in patients with progressive bone
disease. Urinary calcium excretion does not change in the presence
of sclerotic bone metastases, whereas urinary cross-link excretion
was shown to be elevated (Sano et al, 1994). In this study, 50% of
the women had an element of sclerotic bone disease, and this may
account for the failure of urinary calcium excretion to increase
with disease progression. As with other markers of bone disease,
elevation of urinary cross-link levels must be related to other clin-
ical and biochemical markers as elevations of urinary cross-links
could occur from benign bone disease. These results confirm work
by Sano et al (1994) that bone resorption is also elevated in
patients with osteosclerotic bone metastases despite the
osteoblastic overactivity seen on histological and radiological
study of such metastases. This study has demonstrated that
sequential monitoring of urinary cross-link levels during therapy
may prove to be a useful indicator of disease response in bone.
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